nach oben

Current Diabetes Reports

Erschienen in:

01.11.2019 | Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

Personalized Management of Type 2 Diabetes

verfasst von: Patricia R. Peter, Beatrice C. Lupsa

Erschienen in: Current Diabetes Reports | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Our goal is to discuss how to personalize the management of patients with type 2 diabetes by adjusting glycemic targets and tailoring medical therapy to account for unique patient characteristics.

Recent Findings

We review the pharmacotherapeutic options for the management of type 2 diabetes, focusing on potential advantages and disadvantages of each class of agents. We also discuss how to approach specific patient subpopulations and propose a conceptual framework for incorporating these factors into clinical practice.

Summary

As the diabetes treatment landscape rapidly expands, physicians have the exciting opportunity to offer patients increasingly individualized care.

Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14. https://doi.org/10.1016/j.diabres.2009.10.007.CrossRefPubMed

National Diabetes Statistics Report. 2017. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed 25 June 2019.

American Diabetes A. Economic costs of Diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–28. https://doi.org/10.2337/dci18-0007.CrossRef

Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370(16):1514–23. https://doi.org/10.1056/NEJMoa1310799.CrossRefPubMed

American Diabetes A. 5. Lifestyle management: standards of medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S46–60. https://doi.org/10.2337/dc19-S005.CrossRef

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–65.CrossRef

Bain S, Druyts E, Balijepalli C, Baxter CA, Currie CJ, Das R, et al. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: a Bayesian meta-analysis of survival data. Diabetes Obes Metab. 2017;19(3):329–35. https://doi.org/10.1111/dom.12821.CrossRefPubMed

Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(10):938–53. https://doi.org/10.1111/dom.12116.CrossRefPubMed

Varvaki Rados D, Catani Pinto L, Reck Remonti L, Bauermann Leitao C, Gross JL. The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med. 2016;13(4):e1001992. https://doi.org/10.1371/journal.pmed.1001992.CrossRefPubMedPubMedCentral

10.

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89. https://doi.org/10.1016/S0140-6736(05)67528-9.CrossRefPubMed

11.

Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374(14):1321–31. https://doi.org/10.1056/NEJMoa1506930.CrossRefPubMedPubMedCentral

12.

Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164(19):2097–104. https://doi.org/10.1001/archinte.164.19.2097.CrossRefPubMed

13.

Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165(5):305–15. https://doi.org/10.7326/M15-1774.CrossRefPubMed

14.

Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85. https://doi.org/10.1056/NEJMoa0907929.CrossRefPubMedPubMedCentral

15.

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57. https://doi.org/10.1002/hep.29367.CrossRefPubMed

16.

Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370(9593):1129–36. https://doi.org/10.1016/S0140-6736(07)61514-1.CrossRefPubMed

17.

Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007;30(8):2148–53. https://doi.org/10.2337/dc07-0141.CrossRefPubMed

18.

Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71. https://doi.org/10.1056/NEJMoa072761.CrossRefPubMed

19.

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125–35. https://doi.org/10.1016/S0140-6736(09)60953-3.CrossRefPubMed

20.

Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int. 2008;19(2):129–37. https://doi.org/10.1007/s00198-007-0477-y.CrossRefPubMed

21.

Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006;91(9):3349–54. https://doi.org/10.1210/jc.2005-2226.CrossRefPubMed

22.

Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007;92(4):1305–10. https://doi.org/10.1210/jc.2006-2646.CrossRefPubMed

23.

Filipova E, Uzunova K, Kalinov K, Vekov T. Pioglitazone and the risk of bladder cancer: a meta-analysis. Diabetes Ther. 2017;8(4):705–26. https://doi.org/10.1007/s13300-017-0273-4.CrossRefPubMedPubMedCentral

24.

Tang H, Shi W, Fu S, Wang T, Zhai S, Song Y, et al. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. Cancer Med. 2018;7(4):1070–80. https://doi.org/10.1002/cam4.1354.CrossRefPubMedPubMedCentral

25.

Tolman KG, Freston JW, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf. 2009;32(9):787–800. https://doi.org/10.2165/11316510-000000000-00000.CrossRefPubMed

26.

Tkac I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care. 2017;40(2):284–6. https://doi.org/10.2337/dc15-1707.CrossRefPubMed

27.

Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P, et al. Pancreatic safety of Sitagliptin in the TECOS study. Diabetes Care. 2017;40(2):164–70. https://doi.org/10.2337/dc15-2780.CrossRefPubMed

28.

DeVries JH, Rosenstock J. DPP-4 inhibitor-related pancreatitis: rare but real! Diabetes Care. 2017;40(2):161–3. https://doi.org/10.2337/dci16-0035.CrossRefPubMed

29.

Pinto LC, Rados DV, Barkan SS, Leitao CB, Gross JL. Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis. Sci Rep. 2018;8(1):782. https://doi.org/10.1038/s41598-017-19055-6.CrossRefPubMedPubMedCentral

30.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42. https://doi.org/10.1056/NEJMoa1501352.CrossRefPubMed

31.

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69–79. https://doi.org/10.1001/jama.2018.18269.CrossRefPubMed

32.

Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–88. https://doi.org/10.1161/CIRCULATIONAHA.114.010389.CrossRefPubMed

33.

Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–76. https://doi.org/10.1016/S0140-6736(14)62225-X.CrossRefPubMed

34.

Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460–70. https://doi.org/10.1001/jama.2017.14752.CrossRefPubMedPubMedCentral

35.

•• Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. https://doi.org/10.1056/NEJMoa1603827. The LEADER trial studied over 9000 T2DM patients at high CVD risk and showed that treatment with liraglutide led to a 13% reduction in the primary composite cardiac outcome and a 22% reduction in CV death when compared to placebo. CrossRefPubMedPubMedCentral

36.

•• Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–44. https://doi.org/10.1056/NEJMoa1607141. SUSTAIN-6 studied over 3000 T2DM patients at high CVD risk and found a 26% reduction in the primary composite cardiac outcome and a 12% reduction in progression of nephropathy in those treated with semaglutide versus placebo. CrossRefPubMed

37.

Mann JFE, Orsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839–48. https://doi.org/10.1056/NEJMoa1616011.CrossRefPubMed

38.

Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–90. https://doi.org/10.1016/S0140-6736(15)00803-X.CrossRefPubMed

39.

Questions and Answers - Safety Requirements for Victoza (liraglutide). https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/questions-and-answers-safety-requirements-victoza-liraglutide. Accessed 25 June 2019.

40.

Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014;348:g2366. https://doi.org/10.1136/bmj.g2366.CrossRefPubMedPubMedCentral

41.

Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. Diabetes Res Clin Pract. 2014;103(2):269–75. https://doi.org/10.1016/j.diabres.2014.01.010.CrossRefPubMed

42.

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. https://doi.org/10.1056/NEJMoa1411892.CrossRefPubMed

43.

Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes Obes Metab. 2017;19(9):1233–41. https://doi.org/10.1111/dom.12926.CrossRefPubMed

44.

Faillie JL, Yu OH, Yin H, Hillaire-Buys D, Barkun A, Azoulay L. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 Diabetes mellitus. JAMA Intern Med. 2016;176(10):1474–81. https://doi.org/10.1001/jamainternmed.2016.1531.CrossRefPubMed

45.

FDA briefing materials - Liraglutide (April 2009) www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4422b2-01-FDA.pdf. Accessed April 2019.

46.

Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473–86. https://doi.org/10.1210/en.2009-1272.CrossRefPubMed

47.

Andreadis P, Karagiannis T, Malandris K, Avgerinos I, Liakos A, Manolopoulos A, et al. Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20(9):2255–63. https://doi.org/10.1111/dom.13361.CrossRefPubMed

48.

Vilsboll T, Bain SC, Leiter LA, Lingvay I, Matthews D, Simo R, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889–97. https://doi.org/10.1111/dom.13172.CrossRefPubMedPubMedCentral

49.

Fadini GP, Sarangdhar M, Avogaro A. Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System. BMJ Open Diabetes Res Care. 2018;6(1):e000475. https://doi.org/10.1136/bmjdrc-2017-000475.CrossRefPubMedPubMedCentral

50.

Sharma T, Paixao R, Villabona C. GLP-1 agonist associated acute kidney injury: a case report and review. Diabetes Metab. 2017. https://doi.org/10.1016/j.diabet.2017.12.002.CrossRef

51.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720.CrossRefPubMed

52.

•• Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. https://doi.org/10.1056/NEJMoa1611925. The CANVAS trial studied over 10,000 T2DM patients at risk for CVD who were treated with canagliflozin and found a 14% reduction in the primary composite cardiac outcome when compared to placebo. CrossRefPubMed

53.

Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137(4):323–34. https://doi.org/10.1161/CIRCULATIONAHA.117.032038.CrossRefPubMedPubMedCentral

54.

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–34. https://doi.org/10.1056/NEJMoa1515920.CrossRefPubMed

55.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. https://doi.org/10.1056/NEJMoa1812389.CrossRefPubMed

56.

Shibuya T, Fushimi N, Kawai M, Yoshida Y, Hachiya H, Ito S, et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes Obes Metab. 2018;20(2):438–42. https://doi.org/10.1111/dom.13061.CrossRefPubMed

57.

Ito D, Shimizu S, Inoue K, Saito D, Yanagisawa M, Inukai K, et al. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care. 2017;40(10):1364–72. https://doi.org/10.2337/dc17-0518.CrossRefPubMed

58.

Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53(3):362–76. https://doi.org/10.1007/s00535-017-1415-1.CrossRefPubMed

59.

Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262–74. https://doi.org/10.7326/0003-4819-159-4-201308200-00007.CrossRefPubMed

60.

Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687–93. https://doi.org/10.2337/dc15-0843.CrossRefPubMedPubMedCentral

61.

Palmer BF, Clegg DJ, Taylor SI, Weir MR. Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney. J Diabetes Complicat. 2016;30(6):1162–6. https://doi.org/10.1016/j.jdiacomp.2016.05.008.CrossRef

62.

Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017;376(23):2300–2. https://doi.org/10.1056/NEJMc1701990.CrossRefPubMed

63.

Investigators OT, Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28. https://doi.org/10.1056/NEJMoa1203858.CrossRef

64.

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723–32. https://doi.org/10.1056/NEJMoa1615692.CrossRefPubMedPubMedCentral

65.

Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17(4):386–94. https://doi.org/10.1111/dom.12438.CrossRefPubMedPubMedCentral

66.

Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA. 2017;318(1):45–56. https://doi.org/10.1001/jama.2017.7117.CrossRefPubMedPubMedCentral

67.

American DA. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S90–S102. https://doi.org/10.2337/dc19-S009.CrossRef

68.

American Diabetes A. 6. Glycemic targets: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S61–70. https://doi.org/10.2337/dc19-S006.CrossRef

69.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89. https://doi.org/10.1056/NEJMoa0806470.CrossRefPubMed

70.

Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in type 2 Diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–701. https://doi.org/10.2337/dci18-0033.CrossRefPubMedPubMedCentral

71.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2019 executive summary. Endocr Pract. 2019;25(1):69–100. https://doi.org/10.4158/CS-2018-0535.CrossRefPubMed

72.

LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1520–74. https://doi.org/10.1210/jc.2019-00198.CrossRefPubMedPubMedCentral

73.

American Diabetes A. 12. Older adults: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S139–S47. https://doi.org/10.2337/dc19-S012.CrossRef

74.

American Diabetes A. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S103–S23. https://doi.org/10.2337/dc19-S010.CrossRef

75.

United States Renal Data System. Chapter 1: CKD in the General Population. https://www.usrds.org/2018/view/v1_01.aspx. Accessed 25 June 2019.

Titel: Personalized Management of Type 2 Diabetes
verfasst von: Patricia R. Peter
Beatrice C. Lupsa
Publikationsdatum: 01.11.2019
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 11/2019
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-019-1244-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2019

Pregnancy and Gestational Diabetes Mellitus (GDM) in North American Indian Adolescents and Young Adults (AYA): Implications for Girls and Stopping GDM

Correction to: Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition

USA Vs Europe: Who Is Leading the Diabetes Tech Race?

Updates in Glycemic Management in the Hospital

Pancreas Transplantation from Donors after Circulatory Death: an Irrational Reluctance?

Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes